Go online to PeerView.com/JST860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The management of patients with desmoid tumors is currently transitioning from surgical approaches to more conservative strategies by utilizing systemic therapy. The discovery that desmoid tumors are almost universally associated with genetic alterations in the Wnt/β-catenin pathway has provided rationale for the development of gamma secretase inhibitors (GSIs), a new promising class of agents, and several are in late-phase testing. Although no systemic therapies have received regulatory approval for the treatment of desmoid tumors to date, it is important to be prepared to learn how to integrate GSIs into practice. This PeerView educational activity, based on a recent live symposium, features a panel of leading experts in managing patients with desmoid tumors. The faculty provide expert insights and practical guidance for navigating the latest treatment advances, including GSIs, for desmoid tumors. In addition, illustrative cases and clinical scenarios are discussed to demonstrate the emerging role and integration of novel GSIs in real-world patient care settings. Upon completion of this activity, participants should be better able to: Describe the epidemiology, predisposing factors, molecular pathogenesis, and clinical characteristics of adult and pediatric desmoid tumors; Implement validated strategies that harness multidisciplinary team-based approaches to diagnose desmoid tumors, including referring patients to sarcoma specialists; and Integrate novel therapeutic approaches based on current evidence to include emerging therapies in the context of clinical trial enrollment into the treatment plans of patients with desmoid tumors